Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Jim Dimitroulakos, Patrick James Villeneuve, Harmanjatinder S. Sekhon, Theodore J. Perkins, Mohamed S. Hasim, David J. Stewart, Tabassom Baghai, Nima Niknejad, Jair Bar
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 525-535 (2016)
Non–small cell lung carcinoma (NSCLC) is the most common cause of cancer deaths, with platin-based combination chemotherapy the most efficacious therapies. Gains in overall survival are modest, highlighting the need for novel therapeutic approaches
Autor:
Muneesh Tewari, Alexander Zaslavsky, Todd M. Morgan, Audrey Gloeckner-Kalousek, Felix Y. Feng, Harene Venghatakrishnan, Arun Sreekumar, Ganesh S. Palapattu, Nagireddy Putluri, Hangwen Li, Mackenzie Adams
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 17, Iss 6, Pp 490-496 (2015)
Platelets have been long postulated to play a critical role in the pathogenesis of prostate cancer, although relatively little is known regarding the precise mechanisms involved. Androgen deprivation therapy (ADT) for prostate cancer eventually fails
Autor:
Chitra Subramanian, Jason A. Jarzembowski, Roland P.S. Kwok, Valerie P. Castle, Anthony W. Opipari
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 9, Iss 6, Pp 495-503 (2007)
The cytotoxic mechanism of the histone deacetylase inhibitor (HDACI) Trichostatin A (TSA) was explored in a neuroblastoma (NB) model. TSA induces cell death in neuroblastic-type NB cells by increasing the acetylation of Ku70, a Bax-binding protein. K
Autor:
Kaunteya Reddy, Raju C. Reddy, Anjaiah Srirangam, Srinivasareddy Gangireddy, Theodore J. Standiford, Jun Chen, Gregory P. Kalemkerian, Venkateshwar G. Keshamouni
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 10, Iss 6, Pp 597-603 (2008)
Preclinical studies have shown that peroxisome proliferator-activated receptor gamma (PPAR-gamma) ligands can exert antitumor effects against non-small cell lung cancer (NSCLC) and a variety of other cancers. In this study, we investigate the potenti
Autor:
Gerben M. Franssen, Otto C. Boerman, Peter F.A. Mulders, Mirjam de Weijert, William P.J. Leenders, Jeroen van der Laak, J.C. Oosterwijk-Wakka, Egbert Oosterwijk
Publikováno v:
Neoplasia, 17, 2, pp. 215-24
Neoplasia: An International Journal for Oncology Research, Vol 17, Iss 2, Pp 215-224 (2015)
Neoplasia, 17, 215-24
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 17, Iss 2, Pp 215-224 (2015)
Neoplasia, 17, 215-24
Neoplasia (New York, N.Y.)
Contains fulltext : 154027.pdf (Publisher’s version ) (Open Access) Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC re
Autor:
Takamitsu Sasaki, Kenji Yokoi, Isaiah J. Fidler, Paul J. Chiao, Do Hyun Nam, Stanley R. Hamilton, Sun Jin Kim, Junqin He, James L. Abbruzzese, Premal H. Thaker, Guido M. Sclabas, Sertac Yazici
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 7, Iss 7, Pp 696-704 (2005)
Although gemcitabine has been accepted as the first-line chemotherapeutic reagent for advanced pancreatic cancer, improvement of response rate and survival is not sufficient and patients often develop resistance. We hypothesized that the inhibition o
Autor:
Jonathan T. Sims, Shyng-Shiou F. Yuan, Susan E. Waltz, Hsueh-Ling Chang, Yi-Chen Lee, Huajun Zhao, Ming-Feng Hou, Rina Plattner, I-Fen Chen, Fu Ou-Yang, Shao Chun Wang, Shuk-Mei Ho
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 3, Pp 214-223 (2010)
Targeting the estrogen receptor is an important strategy in breast cancer therapy. However, although inhibiting estrogen receptor function with specific estrogen receptor modulators can achieve a primary response in cancer patients, intrinsic or subs